Abbott (ABT) July 103 straddle into quarter results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/10/2026
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Brent climbs $1 on uncertainty over end to Iran war
- Atlassian results seen as 'game changer' for AI kills software worries
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Atlassian results seen as 'game changer' for AI kills software worries
- Microsoft only US hyperscaler with positive free cash flow as AI capex bites
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Evercore ISI Reiterates Outperform Rating on Abbott Labs (ABT), PT $120
July 18, 2024 8:59 AM EDTEvercore ISI analyst Vijay Kumar reiterated an Outperform rating and $120.00 price target on Abbott Labs (NYSE: ABT).
The analyst comments "ABT reported base organic revenue growth rate of ~9.3% excl. COVID, with overall revenues coming inline with ST. Fx came in ~50 bps worse than Guide, ex which total revs would have Beat slightly. This was a clean print and there were no China VBP call outs, distributor stocking dynamics or China anti-corruption impact in the Q (notable given JNJ called these out yesterday). The organic revenue growth... More
TD Cowen Reiterates Buy Rating on Abbott Labs (ABT), PT $130
July 18, 2024 8:53 AM EDTTD Cowen analyst Joshua Jennings reiterated a Buy rating and $130.00 price target on Abbott Labs (NYSE: ABT).
The analyst comments "Second-quarter revenue and EPS of $10.38B and $1.14 beat the Street's $10.37B and $1.11 forecasts. Organic sales growth for the base business, excluding Covid test sales,... More
Stifel Reiterates Buy Rating on Abbott Labs (ABT)
July 18, 2024 8:50 AM EDTStifel analyst Rick Wise reiterated a Buy rating and $115.00 price target on Abbott Labs (NYSE: ABT).
The analyst comments "Delivering the sixth quarter in a row of double-digit Medical Device division (43% of 2Q sales) growth, Abbotts 2Q solid performance met expectations. As a whole, we view the companys Medical Device growth and 2H24 positive momentum commentary as a... More
Citi Reiterates Buy Rating on Abbott Labs (ABT)
July 18, 2024 8:49 AM EDTCiti analyst Joanna Wuensch reiterated a Buy rating and $119.00 price target on Abbott Labs (NYSE: ABT).
The analyst comments "Abbott delivered 2Q24 revenue of $10.38B (up 4.0% reported; up 9.3% organic ex-Covid-19), roughly in-line with consensuss $10.37B, including: Nutrition of $2.15B (up 7.5%, versus $2.16B); Diagnostics of $2.20B... More
